Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Specialties
Hematology
Oncology
Musculoskeletal Disorder
Rare Disease
Metabolic Disorder
Cardiovascular Disease
Ophthalmology
Neurology
Infectious Disease
View all Specialties
Technologies
Cell Therapy
MSC
iPSC
Gene Therapy
Genome Editing
Extracellular Vesicles
CAR-T Therapy
TCR Therapy
Tissue-Engineering & Biomaterials
View all Technologies
Topics
Treatment
Immuno-Oncology
Trial Updates
Perspectives
Manufacturing
COVID-19
View all Topics
Conferences
ASH 2022
TCT 2022
Meeting on the Med 2022
ICLE 2022
Advanced Therapies Week 2022
TERMIS 2021
ESGCT 2021
Meeting on the Mesa 2021
Advanced Therapies 2021
View all Conferences
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Interview
5:15
CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio
• 21 Feb 2023
3:52
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney
• 24 Feb 2023
3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Shah
• 15 Feb 2023
3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah
• 15 Feb 2023
2:47
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
Sergio Giralt
• 17 Feb 2023
3:48
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML
Swati Naik
• 20 Feb 2023
0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball
• 10 Feb 2023
8:25
CAR-T therapy in acute and chronic leukemias: current applications and future outlooks
John Gribben
• 10 Feb 2023
1:05
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA
Hermann Einsele
• 10 Feb 2023
2:21
Exploring the potential role of CD7-targeting CAR-T cells in T-ALL
Maksim Mamonkin
• 10 Feb 2023
2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe
• 10 Feb 2023
2:15
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells
Sascha Haubner
• 10 Feb 2023
1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel
• 9 Feb 2023
1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri
• 9 Feb 2023
5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein
• 9 Dec 2022
1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam
• 12 Dec 2022
1
2
3
4
5
…
39
Next